Associate professor

Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

Retrieved on: 
Montag, Mai 27, 2024
Health, Hospitals, General Health, Research, Pharmaceutical, Science, The central science, University, Disease, Asthma, Teaching hospital, Harvard University, Medicine, Peanut, Allergy, Peanut allergy, Microbiology, MD, University Medical Center, Environmental Health (journal), Research institute, Anaphylaxis, University of Queensland, Murdoch Children's Research Institute, University of Cape Town, Knowledge Organization (journal), File association, Associate professor, Pollen, Public, Epidemiology, Vorstand, Internal medicine, Senior lecturer, Doctor of Philosophy, Prevalence, Food allergy, Stallergenes Greer, History, Public health, Pharmaceutical industry

The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy.

Key Points: 
  • The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy.
  • These awards recognise outstanding contributions to allergy research and environmental health initiatives and allocate up to €150,000 to support these efforts.
  • Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation, expresses his congratulations to the award recipients.
  • “These researchers exemplify the spirit of innovation and dedication that the Stallergenes Greer Foundation seeks to promote.

Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Donnerstag, Mai 23, 2024
Patient, Pharmacokinetics, MD Anderson Cancer Center, Pembrolizumab, PD, University, NK, Clinical trial, Therapy, Associate professor, Safety, Mural, MD, Regulatory T cell, Cancer, ASCO, Poster, Society, Vaccine

WALTHAM, Mass. and DUBLIN, May 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared data from ARTISTRY-3, a clinical trial designed to evaluate the effects of less frequent intravenous dosing (LFIV) of nemvaleukin alfa (nemvaleukin), in advance of the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4 in Chicago.

Key Points: 
  • Mural believes that this seven-day window offers more time for patient recovery and allows for more flexibility both for patients and providers.
  • Mural expects to provide preliminary data readouts from cohort 3 in the first half of 2025 and from cohort 4 in the second half of 2025.
  • The data presented at ASCO demonstrated PD proof of mechanism and promising tolerability across all three dosing schedules.
  • We are immediately incorporating this new dosing regimen into additional cohorts of ARTISTRY-6, our phase 2 trial of nemvaleukin,” said Caroline Loew, Ph.D., CEO of Mural Oncology.

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Retrieved on: 
Donnerstag, Mai 16, 2024
IL-17A, Patient, University of Miami, Food, European Medicines Agency, Clinical trial, University, Depression, FDA, Associate professor, Moonlake, Single-domain antibody, Inflammation, MIRA, EMA, Tissue, Scar, HS, Pain, VELA, MAS, Pharmaceutical industry

Sonelokimab is designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues.

Key Points: 
  • Sonelokimab is designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues.
  • Following the positive results from the landmark Phase 2 MIRA trial, the Phase 3 VELA program is expected to enroll 800 patients across VELA-1 and VELA-2.
  • The Phase 3 program will use a protocol design consistent with the Phase 2 MIRA trial, which identified the optimal dose of sonelokimab for HS.
  • The topline primary endpoint readout (week 16) from the VELA program is expected as of mid-2025.

NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting

Retrieved on: 
Donnerstag, Mai 23, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, General Health, Other Science, Science, Probability, HLA, Patient, MDS, Acute myeloid leukemia, PBSC, Risk, Haematopoietic system, Sickle cell disease, Associate professor, Bone marrow, Medical college, MMUD, AML, ALL, Observational study, Transplant, ASCO, ACCESS, Myelodysplastic syndrome, Acute lymphoblastic leukemia, GRFS, OS, Society, All, Hematology, Graft-versus-host disease, Quality of life, NMDP, Annual general meeting, City, Dentistry

Notably, ASCO also selected this abstract to be presented at its 2024 Best of ASCO program in July.

Key Points: 
  • Notably, ASCO also selected this abstract to be presented at its 2024 Best of ASCO program in July.
  • Notably, half of patients enrolled in the trial were people of color.
  • NMDP’s network of transplant centers, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established stem cell transplantation science.
  • “Through CIBMTR, we are showing that science can solve the gap in equitable access to transplant, giving new hope to patients worldwide.”
    Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need

CACI Sets Another Distance Record for Optical Communications

Retrieved on: 
Donnerstag, Mai 23, 2024
Software, Mobile, Wireless, Networks, Contracts, Technology, Defense, Security, Satellite, Government Technology, Aerospace, Manufacturing, Telecommunications, OEM, NASA, OCT, Government, Deep Space Optical Communications, DSOC, CACI, Associate professor, Jet Propulsion Laboratory, LEO, Multimedia, Communications satellite

Using CACI International Inc’s ( NYSE: CACI ) optical communications technology, NASA successfully sent data from its Psyche spacecraft to the Jet Propulsion Laboratory in Southern California, a distance of more than 200 million kilometers, as part of the Deep Space Optical Communications (DSOC) experiment.

Key Points: 
  • Using CACI International Inc’s ( NYSE: CACI ) optical communications technology, NASA successfully sent data from its Psyche spacecraft to the Jet Propulsion Laboratory in Southern California, a distance of more than 200 million kilometers, as part of the Deep Space Optical Communications (DSOC) experiment.
  • Additionally, NASA will continue to leverage CACI’s optical technology for DSOC as the range is extended.
  • View the full release here: https://www.businesswire.com/news/home/20240523496661/en/
    “With this latest accomplishment, we have achieved another ‘first for mankind’ milestone with our technology,” said John Mengucci , CACI President and Chief Executive Officer.
  • “Our proven optical technology continues to attain historic milestones in the Optical Communications Terminal (OCT) realm.

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Retrieved on: 
Mittwoch, Mai 22, 2024
Biotechnology, Pharmaceutical, Health, ENDO, Congenital adrenal hyperplasia, Polycystic ovary syndrome, PCOS, Feinberg School of Medicine, Endocrine Society, Risk, Treatment, Diabetes, Associate professor, CAH, Division, Associate, Abstract, Mortality, Johns Hopkins University, Metabolism, Molecular medicine, Pharmaceutical industry

Spruce Biosciences, Inc .

Key Points: 
  • Spruce Biosciences, Inc .
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.
  • In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS).
  • Access more information about ENDO 2024 here .

Visier's First Quarter of 2024 Marks Unprecedented Scale in Generative AI Production Use and Transformational Investment in Analytic Platform Capabilities

Retrieved on: 
Dienstag, Mai 14, 2024
Partnership, Telecommunications, Microsoft, Data collection, Learning, Kellogg School, Organization, Privacy, Investment, Data, Associate professor, Government, Partner, HCM, Life, VEE, Harvard Business Review, Prudential Financial, Research, Summit, Builder, Lighthouse, Environment, ROI, Biotechnology, New Age, Creativity, Microsoft Azure, Management

VANCOUVER, BC, May 14, 2024 /PRNewswire/ -- Visier, the globally recognized leader in people analytics and workforce solutions for people-powered business, today announced highlights from its first quarter of the fiscal year, which ended on April 30, 2024.

Key Points: 
  • Unprecedented scale deployment of Visier's AI technology, " Vee for Partners ," to 2.1 million employees of Paycor customers.
  • "Vee is one of the most spectacular examples of generative AI in HR today," said Josh Bersin, globally recognized HR industry analyst.
  • HR professionals need to connect data to diagnose people and business problems, and tools like Vee make this amazingly easy."
  • Visier also drove a strong quarter for renewals, securing contracts with customers in financial services, retail, automotive and government.

AgroFresh to Host 12th Annual Post-Harvest Academy, Solidifying Position as Global Leader in Post-Harvest Solutions for Fresh Produce

Retrieved on: 
Mittwoch, Mai 8, 2024
Washington State University, Plant pathology, Publication, Associate professor, Pathology, Acquisition, Database, Marketing, Associate

PHILADELPHIA, May 8, 2024 /PRNewswire/ -- AgroFresh Solutions, Inc., a global leader in post-harvest solutions for fresh produce, together with recently acquired Pace International, will host the 2024 Post-Harvest Academy on Wednesday, May 8, in Cle Elum, Washington. This year's invitation-only event will focus on the apple industry and feature leading industry voices from Washington State University among other distinguished presenters.

Key Points: 
  • PHILADELPHIA, May 8, 2024 /PRNewswire/ -- AgroFresh Solutions, Inc. , a global leader in post-harvest solutions for fresh produce, together with recently acquired Pace International , will host the 2024 Post-Harvest Academy on Wednesday, May 8, in Cle Elum, Washington.
  • This year's invitation-only event will focus on the apple industry and feature leading industry voices from Washington State University among other distinguished presenters.
  • Additional speakers include Desmond O'Rourke, President, Belrose, Inc., Simone Seifert-Higgins, Regulatory Manager, AgroFresh and Jim Spadafora, Director, Global Product Development, AgroFresh.
  • Belrose, Inc. is renowned for publications such as the World Apple Review, World Pear Review, World Kiwifruit Review and World Sweet Cherry Review.

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

Retrieved on: 
Dienstag, Mai 7, 2024
Doctor of Philosophy, Brain, Traffic barrier, Mouse, Phenotype, Poster, MD, Model, Cell, Deficit spending, Associate professor, STXBP1, AAV, DSM-IV codes, Vivisection, Genetics, Disease, Patient, Liver, Baylor College of Medicine, Society, Gene, Treatment, Neurology, Seizure, Gene expression, Neuron, Annual general meeting, Texas Children's Hospital, Baylor University, Baltimore Convention Center, Vaccine

THOUSAND OAKS, Calif., May 7, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida's gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

Key Points: 
  • Gene therapy for genetic epilepsy due to STXBP1 mutations has not been previously possible because earlier generation adeno-associated viruses (AAVs) or wild-type AAVs could not achieve the level of widespread neuronal transduction required to modify the disease.
  • CAP-002 is a first-in-class next-generation intravenous (IV)-administered gene therapy that achieves brain-wide neuronal expression while simultaneously detargeting the liver.
  • Capsida's wholly owned program is currently in IND-enabling studies and is expected to enter the clinic in the first half of 2025.
  • This level of gene expression raises neuronal STXBP1 protein to levels comparable to those that reversed disease phenotype in the mouse model.

NCCN Policy Summit Encourages Conversation and Action on Sexual Health and Fertility Issues Faced by People with Cancer

Retrieved on: 
Montag, Mai 6, 2024
Education, Adolescence, Fertility, City, Research, National LGBT Cancer Network, Doctor of Philosophy, Gynecologic Oncology (journal), Life, ASCO, Cancer, Concurrent estate, Cervical cancer, Virtual, Cancer prevention, NCCN, Fertility preservation, Infertility, National Comprehensive Cancer Network, Oncology, Survivor, JD, Reproductive Sciences, Quality of life, Patient, OBGYN, Gynaecology, Family, MPH, Division, Fox Chase Cancer Center, Human, Assistant professor, Policy, Associate professor, Obstetrics, UCSF, MBA, Birth control

WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment. Speakers covered a wide range of topics, within the context of gender and sex, intimacy, fertility and reproductive health, treatment side-effects, and the impact of a changing policy landscape in the wake of new laws and judicial decisions.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment.
  • These evidence-based expert consensus recommendations feature best practices for addressing sexual health, fertility, hormone-related symptoms, and many other late and long-term effects from cancer.
  • "It is so important that education about sexual and reproductive health be included into the training of cancer clinicians if these critical health issues are to be addressed in patients' comprehensive cancer care."
  • Two afternoon keynote speakers shared first-hand looks at the issue of reproductive health and fertility preservation for people undergoing cancer care.